Effect of community antiretroviral therapy on treatment outcomes among stable antiretroviral therapy patients in Nigeria: A quasi experimental study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
08
2020
accepted:
05
04
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
7
10
2021
Statut:
epublish
Résumé
This study evaluates the effect of Community Anti-retroviral Groups on Immunologic, Virologic and clinical outcomes of stable Antiretroviral Therapy patients in Nigeria. A cohort of 251 eligible adults (≥18 years) on first-line ART for at least 6 months with CD4 counts >200 cells/mm3 and viral load <1000 c/ml were devolved from 10 healthcare facilities to 51 community antiretroviral therapy groups. Baseline immunologic, virologic and clinical parameters were collected and community antiretroviral therapy group patients were followed up for a year after which Human Immunodeficiency Virus treatment outcomes at the baseline and a year after follow-up were compared using paired sample t-test. All the analyses were performed in STATA version 14. Out of the 251 stable antiretroviral therapy adults enrolled, 186 (75.3%) were female, 52 (22.7%) had attained post-secondary education and the mean age of participants was 38 years (SD: 9.5). Also, 66 (27.9%) were employed while 125 (52.7%) were self-employed and 46(19.41%) unemployed. 246 (98.0%) of the participants were retained in care. While there was no statistically significant change in the CD4 counts (456cells/mm3 vs 481cells/mm3 P-0.489) and Log10 viral load (3.54c/ml vs 3.69c/ml P-0.359) after one year of devolvement into the community, we observed a significant increase in body weight (60.8 vs 65, P-0.01). This study demonstrates that community antiretroviral therapy has a potential of maintaining optimum treatment outcomes while improving adherence and retention, and reducing the burden of HIV treatment on the health facility. This study provides baseline information for further research and vital information for HIV program implementers planning to decentralize the management of stable antiretroviral therapy clients.
Identifiants
pubmed: 33901199
doi: 10.1371/journal.pone.0250345
pii: PONE-D-20-25822
pmc: PMC8075245
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250345Déclaration de conflit d'intérêts
The authors have declared that competing interest exist.
Références
BMJ Glob Health. 2016 Sep 15;1(2):e000010
pubmed: 28588933
PLoS Med. 2007 May;4(5):e115
pubmed: 17472433
BMC Public Health. 2018 Aug 29;18(1):1069
pubmed: 30157896
PLoS Med. 2007 Apr;4(4):e128
pubmed: 17439295
Lancet. 2002 Nov 30;360(9347):1710-1
pubmed: 12480418
PLoS One. 2017 Apr 20;12(4):e0176551
pubmed: 28426757
BMJ Open. 2017 Aug 11;7(8):e016800
pubmed: 28801427
JBI Libr Syst Rev. 2012;10(56):3596-3648
pubmed: 27820502
AIDS Res Treat. 2014;2014:137545
pubmed: 25548659
J Int AIDS Soc. 2009 Sep 29;12:22
pubmed: 19788755
Front Pharmacol. 2017 Nov 23;8:831
pubmed: 29218008
AIDS Res Ther. 2015 Nov 12;12:37
pubmed: 26566390
Syst Rev. 2019 Dec 6;8(1):314
pubmed: 31810482
Lancet. 2002 May 25;359(9320):1851-6
pubmed: 12044394
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
Implement Sci. 2017 Aug 25;12(1):107
pubmed: 28841894
PLoS Med. 2011 Jul;8(7):e1001060
pubmed: 21811405
J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):e9-16
pubmed: 22067665
Curr HIV/AIDS Rep. 2016 Dec;13(6):359-366
pubmed: 27739018
BMC Health Serv Res. 2011 Aug 26;11:205
pubmed: 21871068
J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):e39-44
pubmed: 21084990
PLoS Med. 2017 Feb 21;14(2):e1002240
pubmed: 28222126
AIDS Care. 2018 Dec;30(12):1477-1487
pubmed: 30037312
J Acquir Immune Defic Syndr. 2010 Dec;55(4):483-90
pubmed: 20683336
J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):326-331
pubmed: 27787343
Bull World Health Organ. 2010 Aug 1;88(8):593-600
pubmed: 20680124
PLoS One. 2013;8(2):e56088
pubmed: 23418518
Ann Intern Med. 2000 Jul 4;133(1):21-30
pubmed: 10877736
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
AIDS. 2000 Mar 10;14(4):357-66
pubmed: 10770537
J Nutr. 2003 Jan;133(1):322S-327S
pubmed: 12514319
S Afr Med J. 2004 Oct;94(10):846-50
pubmed: 15532762